Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients: Beyond the Abstract

Colorectal cancer (CRC), the third most common cancer in the Western world, is frequently characterized by aberrant activation of the Wnt signaling pathway.1 In up to 90% of cases this activation is caused by mutations to adenomatous polyposis coli (APC), an important component of the β-catenin destruction complex, which regulates Wnt signaling.2,3  In addition to mutational events, epigenetic changes arise frequently in  CRC, including genome-wide DNA hypomethylation along with promoter hypermethylation to silence tumor suppressor genes.

Another pathway contributing to CRC is DNA mismatch repair, leading to microsatellite instability (MSI) when dysregulated. MSI is frequently caused by promoter hypermethylation of the mismatch repair gene mutL homolog 1 (MLH1), but may also be caused by mutations to MLH1 or other mismatch repair genes.(4) A number of epigenetic events distinguishing the MSI subtype from microsatellite stable (MSS) CRCs have been demonstrated. We have previously shown that methylation of secreted frizzled-related protein 1 (SFRP1), an extracellular Wnt antagonist, is associated with MSS CRC.5 Conversely, methylation of a different Wnt antagonist, dickkopf Wnt signaling pathway inhibitor 1 (DKK1), is associated with MSI-high (MSI-H) CRC.5 Methylation of Wnt5a, which activates non-canonical Wnt signaling, is also associated with MSI. (6)

In order to explore CRC subtype-specific methylation events occurring at Wnt signaling genes, we selected two genes for further analysis, APC and immunoglobulin transcription factor 2 (ITF2). DNA methylation of the tumour suppressor APC has been observed in CRC. However, to what extent APC methylation plays a role in colorectal carcinogenesis is unclear, as a wide range of methylation levels has been reported. (7-10) Conflicting evidence exists regarding APC methylation in MSI CRCs. Some small-scale studies (MSI tumours N ≤ 29) have suggested that APC methylation may be associated with the MSI subtype but others show no significant difference (MSI tumours N ≤ 44).8,9,11-15 The transcription factor ITF2, a Wnt signaling target gene that is overexpressed in some adenomas and CRCs, is shown to incur methylation in several cancer types.(16-19)

In this study we quantified promoter methylation of ITF2 and APC using the semi-quantitative real-time PCR-based MethyLight technique in two case-case studies nested in population-based CRC cohorts from the Ontario Familial Colorectal Cancer Registry (n = 330) and the Newfoundland Familial Colorectal Cancer Registry (n = 102) comparing tumour subtypes stratified by MSI status. We also compared methylation of both genes in matched non-neoplastic colorectal mucosa and tumour (n = 47). We established a methylation cutoff of 10% in order to dichotomize values into two groups: unmethylated or methylated. Using this cutoff we determined that ITF2 and APC methylation are significantly associated with tumor versus normal state (both P < 1.0×10-). (6)

In our population from Ontario 26.1% of MSS cases incurred ITF2 methylation compared to 42.4% of MSI-H cases (P = 0.002). Similarly in Newfoundland 29.4% of MSS cases and 56.9% of MSI-H cases were methylated (P = 0.005). Ontario and Newfoundland data was then pooled for further analysis. Among MSI-H cases, ITF2 methylation was associated with MLH1 promoter hypermethylation (P = 6.72×10-4). ITF2 methylation was not found to be associated with age, sex, stage, grade, tumour location, histological type, CIMP status, or survival. APC methylation, although tumor-specific, did not show a significant association with MSI status, age, sex, stage, or other clinicopathological variables, indicating that it is a general tumour-specific CRC biomarker.

Based on its high specificity for CRC, APC methylation may offer usefulness as a marker within a panel of other genes for CRC detection and ITF2 may be useful for detection of MSI-H tumours. Future studies to independently validate these findings are warranted, especially in non-invasive biological sources such as serum or stool. Overall, this study has investigated methylation of the Wnt genes APC and ITF2 in two large cohorts of MSI-H and matched MSS CRC tumours and determined that ITF2 methylation is significantly associated with MSI-H tumours while APC methylation is a tumour- specific event in CRC, which does not differ significantly between MSI-H and MSS subtypes or other clinicopathological variables.

Written by Andrea J. Savio1,2 and Bharati Bapat1,2,3

  1. Lunenfeld-Tanenbaum Research Institute, Sinai Health System
  2. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto
  3. Department of Pathology, University Health Network 

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2016;66(1):7–30.
  2. Gao J, Aksoy B, Dogrusov U, Dresdner G, Gross B, Sumer S, et al. Integrative analysis of complex cancer genomics and clinical profiles using cBioPortal. Sci Signal. 2013;6(269):pl1.
  3. Cerami E, Gao J, Dogrusoz U, Gross BE, Onur S, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
  4. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
  5. Rawson JB, Manno M, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, et al. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. Carcinogenesis. Nature Publishing Group; 2011;32(5):741–7.
  6. Rawson JB, Mrkonjic M, Daftary D, Dicks E, Buchanan DD, Younghusband HB, et al. Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients. Br J Cancer. 2011;104(12):1906–12.
  7. Chen J, Röcken C, Lofton-Day C, Schulz H-U, Müller O, Kutzner N, et al. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis. 2005;26(1):37–43.
  8. Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PTM, Herman JG, et al. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis. 2008;29(2):434–9.
  9. Kumar K, Brim H, Giardiello F, Smoot DT, Nouraie M, Lee EL, et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite Instability sporadic colorectal cancer in African Americans. Clin Cancer Res. 2009;15(4):1155–61.
  10. Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M, Mostafavi-Pour Z. Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep. 2012;39(5):6171–8
  11. Naghibalhossaini F, Zamani M, Mokarram P, Khalili I, Rasti M, Mostafavi-Pour Z. Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep. 2012;39(5):6171–8.
  12. Gay LJ, Mitrou PN, Keen J, Bowman R, Naguib A, Cooke J, et al. Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol. 2012;228(3):405–15.
  13. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer. Gastroenterology. 2007;132(1):127–38.
  14. Kim JC, Choi JS, Roh S a, Cho DH, Kim TW, Kim YS. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann Surg Oncol. 2010;17(7):1767–76.
  15. Thorstensen L, Lind GE, Løvig T, Diep CB, Meling GI, Rognum TO, et al. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia. 2005;7(2):99–108.
  16. Kolligs FT, Nieman MT, Winer I, Hu G, van Mater D, Feng Y, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell. 2002;1(2):145–55.
  17. Herbst A, Bommer GT, Kriegl L, Jung A, Behrens A, Csanadi E, et al. ITF-2 Is Disrupted via Allelic Loss of Chromosome 18q21, and ITF-2B Expression Is Lost at the Adenoma- Carcinoma Transition. Gastroenterology. 2009;137(2):639–48.
  18. Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY, Lee KH, et al. Methylation of transcription factor 4 in gastric carcinoma. Ann Surg Oncol. 2010;17:3344-53.
  19. Kim JH, Kim M, Noh SM, Song KS, Kang GH, Kim HJ et al. CpG methylation in exon 1 of transcription factor 4 increases with age in normal gastric mucosa and is associated with gene silencing in intestinal-type gastric cancers. Carcinogenesis. 2008;29:1623-31.